BIOVENTUS
Bioventus, a global leader in active orthopaedic healing, today unveiled the next generation of its market-leading1 EXOGEN® Ultrasound Bone Healing System. The new EXOGEN has begun shipping in Europe and will be released in the United States, Canada and Australia later this year.
EXOGEN – the clinically proven treatment for indicated* bone fractures – is a medical device that helps fractured bones heal. The device:
- uses safe, effective low-intensity pulsed ultrasound to help stimulate the body’s natural healing process2
- has an 86% heal rate for fractures not healing on their own3
- offers 38% faster healing of indicated fresh fractures4
- received guidance from the UK’s National Institute for Health and Care Excellence (NICE) supporting the use of the cost-effective device (guidance MTG12) as an alternative to surgery for nonunions
The new version of EXOGEN introduces new compliance capabilities – such as a log and patient treatment history – to help physicians ensure that patients are appropriately using and benefiting from the device.
“The value of EXOGEN and how it helps fracture patients has long been known and documented,” explained Duncan Fatkin, Vice President of Global Marketing and Reimbursement for Bioventus. “However, patients may not see results unless they adhere to their physician’s prescribed treatment regimen. That’s a theme we heard over and over again as we partnered with physicians, payers and patients to develop the next generation EXOGEN. Achieving better healing outcomes for patients was something they asked us to focus on, and our new features including the reminder calendar address this.”
"The acceleration and promotion of bone healing continues to be an important goal in the treatment of fractures, non-unions and limb reconstruction. Research continues but progress is slow and demanding,” said Gavin De Kiewiet, Director of Trauma for Limb Reconstruction for Sunderland Royal Hospital in the UK. “The EXOGEN device with low-intensity pulsed ultrasound has greatly contributed to our ability to help these patients. Backed by sound basic science research, level 1 studies and published successful treatment trials, EXOGEN has significantly enhanced treatment modalities available to all clinicians. Patient friendly, doctor successful, and importantly today, cost effective, it is a treatment that has significantly aided our treatment of fractures and non-unions."
Prescribed by thousands of physicians around the world, EXOGEN is a portable, lightweight device that features an ultrasound probe that patients place on their skin at the site of the bone break for 20 minutes a day. Patients can easily perform the treatment at home, and EXOGEN has no known contraindications.
The new EXOGEN replaces the previous models available in Europe – EXOGEN 4000+ and EXOGEN Express. The new device is more portable and user friendly, with its new color LCD screen, splash-proof casing, and sleeker, lightweight design; more environmentally friendly, with its removable, rechargeable battery; and more adaptable with an SD card that determines the number of treatments for the device.
For more information about EXOGEN, visit www.exogen.com .
About Bioventus
Bioventus is a biologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company’s innovative products include market-leading devices, therapies and diagnostics that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com or follow the company on Facebook (www.facebook.com/bioventus ) or Twitter (@BioventusGlobal / www.twitter.com/BioventusGlobal ).
EXOGEN and the Bioventus logo are registered trademarks of Bioventus LLC.
*A non-union is considered to be established when the fracture site shows no visibly progressive signs of healing.
1. Based on company reports for global sales Jan-Dec 2011
2. Azuma Y, Ito M, Harada Y, Takagi H, Ohta T, Jingushi S. Low-intensity pulsed ultrasound accelerates rat femoral fracture healing by acting on the various cellular reactions in the fracture callus. J Bone Miner Res . 2001;16(4):671-680.
3. Nolte PA, van der Krans A, Patka P, Janssen JMC, Ryaby JP, Albers GHR. Low-intensity ultrasound in the treatment of nonunions. J Trauma 2001;51:693–703.
4. Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF. Acceleration of tibial fracture-healing by non-invasive, low-intensity pulsed ultrasound. J Bone Joint Surg Am . 1994;76(1):26-34.
EXOGEN summary of indications for use in the EU, Canada and Australia:
EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of osseous defects (excluding vertebra and skull) that includes: Treatment of delayed union and non-unions, accelerating the time to heal of fresh fractures, treatment of stress fractures, accelerating repair following osteotomy, accelerating repair in bone transport procedures, accelerating repair in distraction osteogenesis procedures, treatment of joint fusion. There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found at www.exogen.com .
EXOGEN Summary of Indications for use in the US:
EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions* excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization. There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling, at www.exogen.com or by contacting customer service at 1-800-396-4325.
Contact:
Bioventus
Michael Vinegrad, +44 (0)7714 953923
michael.vinegrad@BioventusGlobal.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care10.5.2025 12:45:00 CEST | Press release
Data presented at ADHD World Congress highlights how QbCheck supports diagnostic accuracy and individualized treatment monitoring, enabling efficient and robust care in virtual settings. News Summary: New findings show significant improvements in access, clinician confidence, symptom tracking, and individualized care using objective testing. The study underscores the importance of scalable, evidence-based tools, as many countries, including both the UK and the US, face rising demand for ADHD diagnosis and treatment. The study revealed significant improvements post-treatment, validating clinical practice and better clinician-patient alignment. As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Pra
Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model9.5.2025 15:57:00 CEST | Press release
The Time-Series Transformer AI FX Model forecasts cashflow and FX exposure with more than 90% accuracy, helping businesses reduce FX-related fees Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities. At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays. Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts patterns over time. Ant also created new pre-training and Supervised Fine-Tuning (SFT) frameworks to train the model
IFF Completes Divestiture of Nitrocellulose Business9.5.2025 14:00:00 CEST | Press release
IFF (NYSE: IFF) today announced that it has completed the divestiture of its nitrocellulose business, including Walsrode Industrial Park in lower Saxony, Germany, to Czechoslovak Group (CSG). The business manufactures nitrocellulose strictly for industrial purposes, serving customers primarily in coatings and printing inks, and had been part of IFF’s Pharma Solutions business unit. “The divestiture of our nitrocellulose business builds upon our deleveraging journey and enables us to focus on our core businesses,” said Erik Fyrwald, IFF CEO. “I’d like to thank our nitrocellulose colleagues for their dedication and wish them continued success as part of CSG.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Le
Monument Re Transfers €1.4bn Greycastle Portfolio to RGA and Strengthens European Life Insurance Consolidation Platform9.5.2025 14:00:00 CEST | Press release
Monument Re Limited (“Monument”) announces today that it has transferred a legacy €1.4bn reinsurance portfolio, comprising annuity and other life insurance liabilities acquired as part of the 2020 Greycastle transaction, to RGA Americas Reinsurance Company, Ltd. (“RGA”). This transaction releases capital resources that Monument will redirect to its core strategy of consolidation in European life insurance markets. The transaction completed on 2May 2025 following approval by the Boards of Directors of both Monument and RGA and non-objection from the Bermuda Monetary Authority. Monument has taken significant steps in recent months to strengthen its business operations by consolidating its European group support functions in Dublin and by aligning with the recently strengthened regulatory regime in Bermuda. With its strong financial position and best in class capabilities in the Group, Monument remains ideally positioned to build on its success to date and grow its European footprint, del
CPAC Systems AB Announces Strategic Minority Investment in Flying Fish9.5.2025 12:33:00 CEST | Press release
Accelerating the shift toward sustainable and intelligent water mobility CPAC Systems AB, a leader in advanced control systems and embedded vessel and commercial vehicle technology, today announced a strategic minority investment in Flying Fish Maritime Innovations B.V., a pioneer in advanced shared water mobility solutions and robust, cost-effective hydrofoil technology. The investment underscores both companies’ commitment to redefining water-based transportation through innovation, sustainability, and seamless integration. It marks the beginning of a deeper collaboration aimed at enabling smarter, cleaner, and more connected mobility on the water — for both recreational and commercial applications. “We are thrilled to support Flying Fish and their impressive work in redefining water mobility,"saidMarcus Wingolf, CEO of CPAC Systems. "Our investment in Flying Fish represents a strategic alignment of our technical proficiencies and innovative ambitions. This partnership opens exciting
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum